$VISM
VISIUM TECHNOLOGIES, INC. Stock $vism

$vism Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000165495422006715 Filed on May 13, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$555.0K	$1.297M	$1.265M
YoY Change	-28.94%	-52.62%	650.45%
% of Gross Profit
Research & Development	$86.68K	$78.29K	$196.3K
YoY Change	-24.61%	110.4%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$641.6K	$1.375M	$1.351M
YoY Change	-28.38%	-50.43%	652.35%
Operating Profit		-$1.375M	-$1.351M
YoY Change		-49.98%	652.35%
Interest Expense	-$129.3K	-$129.3K	-$445.3K
YoY Change	-116.28%	-174.22%	-38.4%
% of Operating Profit
Other Income/Expense, Net		-$129.3K	$60.04K
YoY Change		-163.66%	-106.08%
Pretax Income	-$583.0K	-$1.504M	-$3.106M
YoY Change	-185.03%	-40.91%	165.99%
Income Tax
% Of Pretax Income
Net Earnings	-$583.0K	-$1.504M	-$1.290M
YoY Change	-185.03%	-40.91%	10.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$225.4K	-$405.10	-$880.20
COMMON SHARES
Basic Shares Outstanding	3.904B shares	3.620B shares
Diluted Shares Outstanding			432.5K shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$137.0K	$352.6K	$361.6K
YoY Change	9.44%	27.7%	616.1%
Cash & Equivalents	$137.0K	$352.6K	$361.6K
Short-Term Investments
Other Short-Term Assets	$0.00	$2.920K	$20.42K
YoY Change	-100.0%
Inventory
Prepaid Expenses	$0.00	$2.917K	$20.42K
Receivables
Other Receivables
Total Short-Term Assets	$137.0K	$355.5K	$382.0K
YoY Change	-24.14%	28.76%	656.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$137.0K	$355.5K	$382.0K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$137.0K	$355.5K	$382.0K
YoY Change	-24.14%	28.76%	656.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$596.5K	$460.9K	$516.2K
YoY Change	40.08%	20.03%
Accrued Expenses	$1.019M	$1.066M	$1.051M
YoY Change	-1.87%	-19.52%	-30.06%
Deferred Revenue
YoY Change
Short-Term Debt	$1.279M	$1.283M	$670.4K
YoY Change	-6.53%	-18.01%	-50.07%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.931M	$3.015M	$2.366M
YoY Change	-2.89%	-31.34%	-43.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.931M	$3.015M	$2.366M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.931M	$3.015M	$2.366M
YoY Change	-2.89%	-31.34%	-43.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.56M	-$55.98M	-$54.47M
YoY Change	10.11%
Common Stock	$288.00	$380.5K	$362.0K
YoY Change	-99.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.794M	-$2.659M	-$1.984M
YoY Change
Total Liabilities & Shareholders Equity	$137.0K	$355.5K	$382.0K
YoY Change	-24.14%	28.76%	656.54%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$583.0K	-$1.504M	-$1.290M
YoY Change	-185.03%	-40.91%	10.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$482.0K	-$819.0K	-$413.2K
YoY Change	154.32%	93.06%	164.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	266.4K	810.0K	-225.0K
YoY Change	590.16%	24.65%	-209.94%
NET CHANGE
Cash From Operating Activities	-482.0K	-819.0K	-413.2K
Cash From Investing Activities
Cash From Financing Activities	266.4K	810.0K	-225.0K
Net Change In Cash	-215.6K	-8.960K	-638.2K
YoY Change	42.85%	-103.97%	-1414.27%
FREE CASH FLOW
Cash From Operating Activities	-$482.0K	-$819.0K	-$413.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3824071242	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3805071235	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3122271108	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2946271099	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	380508	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	294627	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52920474	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51365037	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2659210	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-2837187	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25000	USD
	vism	Warrant Exercise Expense WarrantExerciseExpense	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1296611	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2736524	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3216435	USD
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-76707	USD
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1405081	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-20362	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	855587	USD
CY2022Q1	vism	Derivative Liability Expense DerivativeLiabilityExpense	0	USD
CY2021Q1	vism	Derivative Liability Expense DerivativeLiabilityExpense	1059282	USD
	vism	Derivative Liability Expense DerivativeLiabilityExpense	0	USD
	vism	Derivative Liability Expense DerivativeLiabilityExpense	1059282	USD
CY2021Q1	vism	Warrant Exercise Expense WarrantExerciseExpense	0	USD
	vism	Warrant Exercise Expense WarrantExerciseExpense	211411	USD
CY2022Q1	us-gaap	Interest Expense Other InterestExpenseOther	52587	USD
CY2021Q1	us-gaap	Interest Expense Other InterestExpenseOther	171575	USD
	us-gaap	Interest Expense Other InterestExpenseOther	554262	USD
	us-gaap	Interest Expense Other InterestExpenseOther	247579	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-129294	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	203087	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-574624	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-842686	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1504194	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2545643	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4610474	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4059121	USD
CY2022Q1	vism	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.00
CY2021Q1	vism	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.00
CY2022Q1	vism	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	3713071234	shares
CY2021Q1	vism	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	2769958917	shares
	vism	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	3345074308	shares
	vism	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	1961232893	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1984045	USD
CY2022Q1	vism	Shares Issued For Consulting Services Amount SharesIssuedForConsultingServicesAmount	381300	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	241400	USD
CY2022Q1	vism	Amortization Of Deferred Compensation AmortizationOfDeferredCompensation	40524	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	165802	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1504194	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2659210	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-2837187	USD
	vism	Shares Issued For Consulting Services Amount SharesIssuedForConsultingServicesAmount	1110631	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1059400	USD
	vism	Shares Issued For Exercise Of Warrants Amount SharesIssuedForExerciseOfWarrantsAmount	0	USD
	vism	Amortization Of Deferred Compensation AmortizationOfDeferredCompensation	121572	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4610474	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2659210	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-4171462	USD
CY2021Q1	vism	Shares Issued For Consulting Services Amount SharesIssuedForConsultingServicesAmount	86750	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2419000	USD
CY2021Q1	vism	Shares Issued For Conversion Of Notes Payable And Accrued Interest Amount SharesIssuedForConversionOfNotesPayableAndAccruedInterestAmount	96703	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2545643	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-4114652	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-3380760	USD
	vism	Shares Issued For Consulting Services Amount SharesIssuedForConsultingServicesAmount	125750	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2464000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	133029	USD
	vism	Shares Issued For Conversion Of Notes Payable And Accrued Interest Amount SharesIssuedForConversionOfNotesPayableAndAccruedInterestAmount	391039	USD
	vism	Shares Issued For Exercise Of Warrants Amount SharesIssuedForExerciseOfWarrantsAmount	211411	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4059121	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-4114652	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-20362	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	855587	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3904071242	shares
CY2022Q1	vism	Convertible Notes Payable To Asc Recap Llc ConvertibleNotesPayableToAscRecapLlc	147965	USD
CY2021Q2	vism	Convertible Notes Payable To Asc Recap Llc ConvertibleNotesPayableToAscRecapLlc	147965	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	197400	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	396033	USD
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	930031	USD
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	809195	USD
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	204743	USD
CY2021Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	184381	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	0	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	18252	USD
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	205000	USD
CY2021Q2	us-gaap	Notes Payable Current NotesPayableCurrent	411748	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3014721	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3017771	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2170031	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2589750	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	388842	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	168804	USD
	vism	Warrant Exercise Expense WarrantExerciseExpense	0	USD
	vism	Warrant Exercise Expense WarrantExerciseExpense	211411	USD
	vism	Derivative Liability Expense DerivativeLiabilityExpense	0	USD
	vism	Derivative Liability Expense DerivativeLiabilityExpense	1059282	USD
	vism	Amortization Of Deferred Compensation AmortizationOfDeferredCompensation	121572	USD
	vism	Amortization Of Deferred Compensation AmortizationOfDeferredCompensation	0	USD
	vism	Amortization Of Prepaid Expense AmortizationOfPrepaidExpense	52500	USD
	vism	Amortization Of Prepaid Expense AmortizationOfPrepaidExpense	0	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	180001	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	35092	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	86222	USD
	vism	Discount On Notes Payable DiscountOnNotesPayable	13958	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48217903	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55975512	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3761236	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3098235	USD
CY2022Q1	us-gaap	Other Expenses OtherExpenses	78289	USD
CY2021Q1	us-gaap	Other Expenses OtherExpenses	37206	USD
	us-gaap	Other Expenses OtherExpenses	274614	USD
	us-gaap	Other Expenses OtherExpenses	143200	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1374900	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	2773730	USD
	us-gaap	Operating Expenses OperatingExpenses	4035850	USD
	us-gaap	Operating Expenses OperatingExpenses	3241435	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1374900	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2748730	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4035850	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28863	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-180001	USD
CY2022Q1	vism	Warrant Exercise Expense WarrantExerciseExpense	0	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	vism	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.00
	vism	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.00
	vism	Shares Issued For Conversion Of Notes Payable Amount SharesIssuedForConversionOfNotesPayableAmount	831048	USD
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	165802	USD
	vism	Shares Issued Pursuant To Sale Of Common Stock Amount SharesIssuedPursuantToSaleOfCommonStockAmount	1500000	USD
	vism	Discount On Notes Payable DiscountOnNotesPayable	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	60640	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	53629	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5265	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-37500	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1742572	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-603109	USD
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1500000	USD
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	115000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	73700	USD
	vism	Proceeds From Issuance Of Convertible Notes Payable ProceedsFromIssuanceOfConvertibleNotesPayable	810000	USD
	vism	Proceeds From Issuance Of Convertible Notes Payable ProceedsFromIssuanceOfConvertibleNotesPayable	800000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	225000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	225000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	102340	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1970000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	848960	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	227428	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	245849	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125166	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30251	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	352594	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	276102	USD
	us-gaap	Interest Paid Net InterestPaidNet	22011	USD
	us-gaap	Interest Paid Net InterestPaidNet	40970	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	831048	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	vism	Shares Issued For Financing Amount SharesIssuedForFinancingAmount	165802	USD
	vism	Shares Issued For Financing Amount SharesIssuedForFinancingAmount	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4610474	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1742572	USD
CY2022Q1	vism	Working Capital Deficit WorkingCapitalDeficit	-2659210	USD
	us-gaap	Fiscal Period FiscalPeriod	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Fiscal Year</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fiscal year ends on June 30. References to fiscal year 2022, for example, refer to the fiscal year ending June 30, 2022.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Use of Estimates</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reporting amounts of revenues and expenses during the reported period. Actual results will differ from those estimates. Included in these estimates are assumptions used in Cox, Ross & Rubinstein Binomial Tree stock-based compensation valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate and in the valuation allowance of deferred tax assets and derivative liability.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Concentration of Credit Risks</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains cash with two financial institutions. Deposits held with the financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation on such deposits, but may be redeemed upon demand. The Company performs periodic evaluations of the relative credit standing of the financial institutions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash account is held at a financial institution and is insured by the Federal Deposit Insurance Corporation, or FDIC, up to $250,000.</p>
CY2022Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	204743	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6814782	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	471086872	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	142079692	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	13996767	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3345074308	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1977488957	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	13996767	shares
	vism	Incremental Common Shares Attributable To Common Stock Option IncrementalCommonSharesAttributableToCommonStockOption	3000000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	6814782	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	12165260	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3839972729	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2145730676	shares
	vism	Prepaid License Fee PrepaidLicenseFee	70000	USD
	vism	Conversion Of Warrant Ranging ConversionOfWarrantRanging	from $0.0055 to $0.02 per share exercise price of the warrants
	vism	Recognition Of Gane Loss RecognitionOfGaneLoss	-20362	USD
	vism	Recognition Of Gane Loss RecognitionOfGaneLoss	855587	USD
CY2022Q1	vism	Warrants Fair Value WarrantsFairValue	11730	USD
CY2021Q2	vism	Warrants Fair Value WarrantsFairValue	69334	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	193014	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	184081	USD
	vism	Schedule The Fair Value Of The Warrants And Convertible Debt ScheduleTheFairValueOfTheWarrantsAndConvertibleDebt	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective exercise price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td>$</td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.0014 – $0.02 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td>$ </td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.00361 – $0.02 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective market price</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.0027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.006</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">175.2% to 291.1</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">% </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">96.4% to 304.0</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.35% - 2.28</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.05% - 0.25</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">% </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected terms</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">60 – 915 days</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">60 - 711 days</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected dividend rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
CY2022Q1	vism	Derivative Liabilities Fair Value Assumptions Market Price DerivativeLiabilitiesFairValueAssumptionsMarketPrice	0.0027
CY2021Q1	vism	Derivative Liabilities Fair Value Assumptions Market Price DerivativeLiabilitiesFairValueAssumptionsMarketPrice	0.006
	vism	Derivative Liabilities Fair Value Assumptions Expected Dividend Rate DerivativeLiabilitiesFairValueAssumptionsExpectedDividendRate	0	pure
	vism	Derivative Liabilities Fair Value Assumptions Expected Dividend Rate DerivativeLiabilitiesFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q2	vism	Derivative Liabilities Beginning DerivativeLiabilitiesBeginning	184381	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	20362	USD
CY2022Q1	vism	Derivative Liabilities Ending DerivativeLiabilitiesEnding	204743	USD
CY2021Q2	us-gaap	Interest Payable Current InterestPayableCurrent	366149	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	100156	USD
	us-gaap	Interest Paid InterestPaid	22011	USD
	vism	Conversion Of Accrued Interest Into Common Stock ConversionOfAccruedInterestIntoCommonStock	-56001	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	388293	USD
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1127431	USD
CY2021Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1205228	USD
CY2022Q1	vism	Discount On Convertible Notes Payable DiscountOnConvertibleNotesPayable	-197400	USD
CY2021Q2	vism	Discount On Convertible Notes Payable DiscountOnConvertibleNotesPayable	-396033	USD
CY2022Q1	vism	Convertible Notes Payable To Related Parties Current ConvertibleNotesPayableToRelatedPartiesCurrent	930031	USD
CY2021Q2	vism	Convertible Notes Payable To Related Parties Current ConvertibleNotesPayableToRelatedPartiesCurrent	809195	USD
CY2021Q2	vism	Convertible Notes Payable To Asc Recap ConvertibleNotesPayableToAscRecap	147965	USD
CY2022Q1	vism	Convertible Notes Payable To Asc Recap ConvertibleNotesPayableToAscRecap	147965	USD
CY2022Q1	us-gaap	Convertible Debt ConvertibleDebt	965796	USD
CY2021Q2	us-gaap	Convertible Debt ConvertibleDebt	957160	USD
CY2013Q3	vism	Principal Amount PrincipalAmount	25000	USD
CY2014Q2	vism	Principal Amount PrincipalAmount	125000	USD
CY2014Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2014-03-31
CY2013Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-05-06
	vism	Description Of Notes Convertible Into The Common Stock DescriptionOfNotesConvertibleIntoTheCommonStock	The notes are convertible into the common stock of the Company at any time at a conversion price equal to (i) 50% of the lowest closing bid price of our common stock for the twenty days prior to conversion or (ii) fixed price of $0.15 or $0.30 per share
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	198046241	shares
	vism	Debt Conversion Converted Instrument Principal DebtConversionConvertedInstrumentPrincipal	772798	USD
	vism	Amount Converted Interest AmountConvertedInterest	56000	USD
	vism	Conversion Expense ConversionExpense	2250	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	831048	USD
CY2022Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.00417
CY2022Q1	vism	Promissory Notes PromissoryNotes	205000	USD
CY2021Q2	vism	Promissory Notes PromissoryNotes	430000	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	198046241	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	831048	USD
CY2022Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.00417
	vism	Shares Issued As Warrent Shares SharesIssuedAsWarrentShares	6587229	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	81000000	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	810000	USD
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0113
CY2022Q1	vism	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	6814782	shares
CY2022Q1	vism	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	0.0113
	vism	Plan Terminates Period PlanTerminatesPeriod	P10Y
	vism	Options Issued For Purchase OptionsIssuedForPurchase	3000000	shares
	vism	Outstanding Exercise Price OutstandingExercisePrice	0.02
	vism	Fair Value Of Options Issued FairValueOfOptionsIssued	0.00
	vism	Recognized Non Cash Compensation Expense RecognizedNonCashCompensationExpense	121572	USD
	vism	Recognized Non Cash Compensation Expense RecognizedNonCashCompensationExpense	0	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	21957	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2500000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	vism	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0000	pure
CY2021	vism	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16000000	shares
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.015
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	13000000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.01385
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000000	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.020
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	0	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M2D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.0110
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	19000000	shares
CY2022Q1	vism	Unrecognized Pre Tax Non Cash Compensation Expense UnrecognizedPreTaxNonCashCompensationExpense	21957	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y2M15D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	132000000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.0115
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	56000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.0071
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	10833333	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0.0080
	vism	Restricted Stock Awards Vested RestrictedStockAwardsVested	-158166667	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.0090
	vism	Unrecognized Compensation Expense UnrecognizedCompensationExpense	113200	USD
CY2022Q1	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	0	USD

Files In Submission

Name	View Source	Status
0001654954-22-006715-index-headers.html	Edgar Link	pending
0001654954-22-006715-index.html	Edgar Link	pending
0001654954-22-006715.txt	Edgar Link	pending
0001654954-22-006715-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vism-20220331.xsd	Edgar Link	pending
vism-20220331_cal.xml	Edgar Link	unprocessable
vism-20220331_def.xml	Edgar Link	unprocessable
vism-20220331_lab.xml	Edgar Link	unprocessable
vism-20220331_pre.xml	Edgar Link	unprocessable
vism_10q.htm	Edgar Link	pending
vism_10qimg1.jpg	Edgar Link	pending
vism_10q_htm.xml	Edgar Link	completed
vism_ex311.htm	Edgar Link	pending
vism_ex312.htm	Edgar Link	pending
vism_ex321.htm	Edgar Link	pending
vism_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VISM
VISIUM TECHNOLOGIES, INC. Stock $vism

2022 Q2 Form 10-Q Financial Statement

#000165495422006715 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VISM VISIUM TECHNOLOGIES, INC. Stock $vism

2022 Q2 Form 10-Q Financial Statement

#000165495422006715 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VISM
VISIUM TECHNOLOGIES, INC. Stock $vism